ABSTRACT
Sex determination is one of the fundamental procedures in the forensic investigation during personal identification. Foot dimensions, prints, indices, and angles are assessment tools used by podiatrists and forensic anthropologists. The arch index remains a tool for clinical evaluation of the incidence of pes planus by clinicians. This cross-sectional study was performed to investigate sexual dimorphism and discriminate sex using foot and footprint dimensions, foot angles, and foot indices among the Ebira ethnic group of Nigeria. Bilateral foot outlines and prints were obtained from 317 females and 283 males using a digital Vernier caliper, improvised footpad, and A4 paper. The results revealed that in the right foot and print, the males' bare right foot length (BRFL), bare right foot breadth (BRFB), right arch index (RAI), right Chippaux-Smirak index (RCSI), right footprint angle (RFPA), right ball angle (RBA), and all the measurements of the corresponding toes in the prints are significantly greater (p < 0.05) than the females. The same trend was also observed in the left footprint except for the left ball angle (LBA). The stepwise, binary logistics regression model for sex determination showed that bare left foot breadth (BLFB) and bare right foot length (BRFL) were the single best predictors of sex with an accuracy of 72.5% and 71.7% accuracy. Other foot variables marginally increased the percentage accuracy at each step. The receiver operating characteristic (ROC) curve analysis confirmed the sexing potential of the bare left foot breadth and bare right foot length to be 79%. Sexual dimorphism exists in all the foot dimensions, arch indices, Chippaux-Smirak indices, footprint angles, and ball angles, except the left ball angle. The sexual dimorphism in the foot variables forms the basis of sex determination, with left foot breadth and right foot length as the best sex predictors. Therefore, 25 cm can be regarded as the cut-off point for foot length and 9 cm as the cut-off point for foot breadth among this tribe.
ABSTRACT
Purpose: The purpose of the study was to determine how camel milk affects hyperglycemia, beta-cell function, oxidative stress, and inflammatory markers in type 2 diabetic pigs. Methods: Twenty-five (25) pigs were separated into five (5) groups of five pigs each, with five (5) non-diabetic and twenty (20) diabetic pigs in each group. Groups 1 and 2 received distilled water as the standard control and diabetic control groups, respectively, while Groups 3 and 4 received camel milk at 250 mL/day and 500 mL/day, respectively, and Group 5 received metformin at 500 mg/day. The experiment lasted ten weeks. At the end of the ten weeks, all the pigs were euthanized. Results: Treatments with camel milk substantially enhance glucose fasting levels by reducing hyperglycemia in diabetic pigs, significant level at (p < 0.05). When pigs given camel milk were compared with untreated diabetic pigs, there was a substantial rise (p < 0.05) in superoxide dismutase (SOD), catalase (CAT), and reduced glutathione (GSH) levels. Also, camel milk substantially lowered the levels of interleukin (IL-1ß) and tumour necrosis factor-alpha (TNF-α) in diabetic pig serum. Similarly, immunohistochemical analysis of islet cells revealed an increase in insulin production, implying improved glycemic control and the eventual commitment of glucose to glycolysis. Conclusion: The bioactive-mediated anti-hyperglycemic and insulin release potential of camel milk treatments contributed to improving type 2 diabetes mellitus. Camel milk improved beta-cell function while reducing oxidative stress and inflammation in type 2 diabetic pigs.
ABSTRACT
Type 2 diabetes occurs as a result of insulin resistance and dysfunction in insulin signaling. Controlling hyperglycemia and activation of insulin signaling are important in the management of type 2 diabetes. This study aimed to evaluate the effect of genistein and Momordica charantia L. fruit (MCF) on oxidative stress, markers of inflammation, and their role in proglucagon and insulin receptor messenger RNA (mRNA) expression by real-time PCR in diabetic rats. Thirty-five albino rats were divided into 7 groups (n = 5). Group I (non-diabetic) and group II (diabetic control) were treated with distilled water, and groups III and IV received 250 mg/kg and 500 mg/kg lyophilized MCF, respectively. Groups V and VI received 10 mg/kg and 20 mg/kg genistein, respectively, while group VII received 500 mg/kg metformin. The administration lasted for 28 days. MCF and genistein significantly reduced interleukin (IL)-1ß and tumor necrosis factor alpha (TNF-α) levels, which were elevated in the serum of diabetic rats. Treatment with MCF and genistein significantly increased the expression of proglucagon mRNA in the small intestine and insulin receptor mRNA in the liver of diabetic rats. In conclusion, MCF and genistein ameliorate type 2 diabetes complications by preventing the loss of insulin-positive cells, inhibiting IL-1ß and TNF-α, and upregulating proglucagon and insulin receptor mRNA expression. Novelty: MCF and genistein have an inhibitory effect on diabetic induced IL-1ß and TNF-α production. MCF and genistein upregulate proglucagon and insulin receptor mRNA expression.
